Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
INTERFERON-ALPHA FOR PROPHYLAXIS OF RECURRENT VIRAL-HEPATITIS-C IN LIVER-TRANSPLANT RECIPIENTS - A PROSPECTIVE, RANDOMIZED, CONTROLLED TRIAL
Autore:
SINGH N; GAYOWSKI T; WANNSTEDT CF; SHAKIL AO; WAGENER MM; FUNG JJ; MARINO IR;
Indirizzi:
VA PITTSBURGH HLTH CARE SYST,INFECT DIS SECT,UNIV DR C PITTSBURGH PA 15240 VET AFFAIRS MED CTR PITTSBURGH PA 00000 UNIV PITTSBURGH,MED CTR,THOMAS E STARZL TRANSPLANTAT INST PITTSBURGH PA 15260
Titolo Testata:
Transplantation
fascicolo: 1, volume: 65, anno: 1998,
pagine: 82 - 86
SICI:
0041-1337(1998)65:1<82:IFPORV>2.0.ZU;2-9
Fonte:
ISI
Lingua:
ENG
Soggetto:
HUMAN-LEUKOCYTE INTERFERON; VIRUS-INFECTION; CYTOMEGALO-VIRUS; RECOMBINANT; REJECTION; ALLOGRAFT; THERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
24
Recensione:
Indirizzi per estratti:
Citazione:
N. Singh et al., "INTERFERON-ALPHA FOR PROPHYLAXIS OF RECURRENT VIRAL-HEPATITIS-C IN LIVER-TRANSPLANT RECIPIENTS - A PROSPECTIVE, RANDOMIZED, CONTROLLED TRIAL", Transplantation, 65(1), 1998, pp. 82-86

Abstract

Background In a randomized, controlled trial, we sought to determine whether prophylaxis with interferon-alpha for 6 months had an impact on rate, severity, and timing of onset of recurrent hepatitis C virus (HCV hepatitis in liver transplant recipients and to assess whether interferon use was associated with re jection in liver transplant recipients. Methods. Twenty-four consecutive liver transplant recipients withHCV were randomized after transplantation to receive either interferon alpha (3 million Il three times weekly) for 6 months or no prophylaxis; median follow-up was 874 days. Results. Recurrent HCV hepatitis (histopathologically proven) developed in 50% (6 of 12) of the interferon-alpha patients versus 42% (5 of 12) of the control patients (P=NS). Severity of recurrence (as assessed by Knodell score on liver biopsies) also did not differ between the two groups (mean 4.0 for interferon-alpha patients versus 3.5 for control patients, P=NS), Interferon alpha, however, significantly delayed the timing of occurrence of HCV hepatitis; recurrent HCV hepatitis developed a median of 408 days after transplant in the interferon-alpha group versus 193 days in the control group (P=0.05). No difference in graft or patient survival was demonstrated in the two groups. Rejection episodes, treated with corticosteroids, occurred in 50% (6 of 12) of patients in the interferon-alpha group versus 42% (5 of 12) in the control group (P=NS). Corticosteroid resistant rejection (requiring OKT3) occurred in only one study patient (in the control group). Conclusions. Interferon-alpha in liver transplant recipients for 6 months delayed the occurrence of HCV hepatitis, but did not decrease the incidence nor the severity of HCV hepatitis after transplantation. Interferon-alpha use was not associated with a higher incidence of rejection compared with the control patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/05/20 alle ore 06:39:53